[{"orgOrder":0,"company":"Moksha8 Pharmaceuticals","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Methylphenidate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Moksha8 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Moksha8 Pharmaceuticals \/ Janssen","highestDevelopmentStatusID":"12","companyTruncated":"Moksha8 Pharmaceuticals \/ Janssen"},{"orgOrder":0,"company":"Moksha8 Pharmaceuticals","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Piracetam","moa":"Ach receptor","graph1":"Neurology","graph2":"Approved","graph3":"Moksha8 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film-coated Tablet","sponsorNew":"Moksha8 Pharmaceuticals \/ UCB","highestDevelopmentStatusID":"12","companyTruncated":"Moksha8 Pharmaceuticals \/ UCB"},{"orgOrder":0,"company":"Moksha8 Pharmaceuticals","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Enavogliflozin","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Moksha8 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Moksha8 Pharmaceuticals \/ Moksha8 Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Moksha8 Pharmaceuticals \/ Moksha8 Pharmaceuticals"},{"orgOrder":0,"company":"Moksha8 Pharmaceuticals","sponsor":"SERB Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Glucarpidase","moa":"","graph1":"Pharmacology\/Toxicology","graph2":"Approved","graph3":"Moksha8 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moksha8 Pharmaceuticals \/ SERB Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Moksha8 Pharmaceuticals \/ SERB Pharmaceuticals"},{"orgOrder":0,"company":"Moksha8 Pharmaceuticals","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Viloxazine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Moksha8 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Moksha8 Pharmaceuticals \/ Moksha8 Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Moksha8 Pharmaceuticals \/ Moksha8 Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals by Moksha8 Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : An agreement aims to seek regulatory approval for Qelbree, an extended-release formulation of viloxazine for ADHD in children and adults.

Brand Name : Qelbree

Molecule Type : Small molecule

Upfront Cash : Undisclosed

May 07, 2024

Lead Product(s) : Viloxazine Hydrochloride

Therapeutic Area : Psychiatry/Psychology

Highest Development Status : Approved

Recipient : Supernus Pharmaceuticals

Deal Size : Undisclosed

Deal Type : Licensing Agreement

blank

02

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : M8 will register, market and commercialize SERB's supportive oncology product Voraxaze (glucarpidase), a carboxypeptidase that reduces toxic plasma methotrexate concentration, in Latin America.

Brand Name : Voraxaze

Molecule Type : Small molecule

Upfront Cash : Undisclosed

March 20, 2024

Lead Product(s) : Glucarpidase

Therapeutic Area : Pharmacology/Toxicology

Highest Development Status : Approved

Sponsor : SERB Pharmaceuticals

Deal Size : Undisclosed

Deal Type : Agreement

blank

03

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : Under the agreement, M8 will have the rights to register and commercialize Envlo™ (enavogliflozin) for Brazil and Mexico. Envlo™ is a SGLT2 (sodium glucose cotransporter 2) inhibitor type diabetes treatment.

Brand Name : Envlo

Molecule Type : Small molecule

Upfront Cash : Undisclosed

February 28, 2023

Lead Product(s) : Enavogliflozin

Therapeutic Area : Endocrinology

Highest Development Status : Approved

Recipient : Daewoong Pharmaceutical

Deal Size : Undisclosed

Deal Type : Licensing Agreement

blank

04

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : According to IQVIA, the portfolio has annual sales of approximately $26 million dollars and includes drugs such as: ATARAX®, NOOTROPIL®, XUZAL®, and VIRLIX®.

Brand Name : Nootropil

Molecule Type : Small molecule

Upfront Cash : Undisclosed

June 22, 2021

Lead Product(s) : Piracetam

Therapeutic Area : Neurology

Highest Development Status : Approved

Sponsor : UCB Pharma S.A

Deal Size : Undisclosed

Deal Type : Partnership

blank

05

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : The strong and diverse portfolio includes: CONCERTA®, HALDOL®, HALDOL® DECANOAS, REMINYL®, SIBELIUM®, RISPERDAL®, RISPERDAL CONSTA® and TOPAMAX®.

Brand Name : Concerta

Molecule Type : Small molecule

Upfront Cash : Undisclosed

September 29, 2020

Lead Product(s) : Methylphenidate

Therapeutic Area : Psychiatry/Psychology

Highest Development Status : Approved

Sponsor : Johnson & Johnson Innovative Medicine

Deal Size : Undisclosed

Deal Type : Agreement

blank